Across TCGA pan-cancer cohorts, NELFE mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NELFE data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NELFE mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NELFE expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where NELFE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.767	0.387	.002	42	view →
PDAC	OS	Median	All	0.396	0.567	.010	16	view →
LSCC	DFS	Tertile	All	0.883	0.566	.005	12	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.923	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NELFE tumor-vs-normal RNA expression · all NELFE data types